José Maria Marcelino

Humoral response in HIV and HCV infection
We are interested in vaccine development; identification, characterization and production of murine and human monoclonal antibodies; neutralization assays using TZM-bl cells; identification of neutralizing viral epitopes; antigenicity and immunogenicity of viral proteins and production of viral particles.

Team: Rute Alexandre Marcelino (PhD Student), Débora Almeida (Master’s Student), Rita Franciosi (Visiting Student)

1. Rocha C, Duarte J, Borrego P, Calado R, Marcelino JM, Tendeiro R, Valadas E, Sousa AE, Taveira N. Potency of HIV-2-specific antibodies increase in direct association with loss of memory B cell. AIDS. 2017 Nov. 13;31(17):2431-243
2. Marcelino JM, Borrego P, Nilsson C, Família C, Barroso H, Maltez F, Doroana M, Antunes F, Quintas A and Taveira N. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism. AIDS. 2012 Nov 28;26 (18):2275-2284. IF = 6.407
3. Marcelino JM, Borrego P, Barroso H, Quintas A, Novo C and Taveira N. Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a Vaccinia vector-prime C2V3C3-boost vaccination strategy. J Virol.  2010 Dec; 84 (23): 12429-12436. IF = 5.189
4. Skar H, Borrego P, Wallstrom TC, Mild M, Marcelino JM, Barroso H, Taveira N, Leitner T, Albert J. HIV-2 genetic evolution in patients with advanced disease is faster than in matched HIV-1. J Virol. 2010 Jul; 84(14): 7412-5. IF = 5.189
5. Marcelino JM, Nilsson C, Barroso H, Gomes P, Borrego P, Maltez F, Rosado L, Doroana M, Antunes F, Taveira N. Envelope-specific antibody response in HIV-2 infection: C2V3C3-specific IgG response is associated with disease progression. 2008 Nov 12; 22(17): 2257-65. IF = 5.460